ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
Total Valuation
ASKA Pharmaceutical Holdings Co., Ltd. has a market cap or net worth of ¥79.23B. The enterprise value is ¥77.11B.
Market Cap¥79.23B
Enterprise Value¥77.11B
Share Statistics
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,763,199
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ASKA Pharmaceutical Holdings Co., Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.05%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.05%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee93.34M
Profits Per Employee7.12M
Employee Count762
Asset Turnover0.63
Inventory Turnover1.27
Valuation Ratios
The current PE Ratio of ASKA Pharmaceutical Holdings Co., Ltd. is 15.3. ASKA Pharmaceutical Holdings Co., Ltd.’s PEG ratio is 1.99.
PE Ratio15.3
PS Ratio0.94
PB Ratio0.96
Price to Fair Value0.96
Price to FCF17.84
Price to Operating Cash Flow0.00
PEG Ratio1.99
Income Statement
In the last 12 months, ASKA Pharmaceutical Holdings Co., Ltd. had revenue of 71.13B and earned 5.42B in profits. Earnings per share was 191.10.
Revenue71.13B
Gross Profit34.15B
Operating Income5.83B
Pretax Income6.99B
Net Income5.42B
EBITDA5.83B
Earnings Per Share (EPS)191.10
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
ASKA Pharmaceutical Holdings Co., Ltd. pays an annual dividend of ¥28, resulting in a dividend yield of 2.52%
Dividend Per Share¥28
Dividend Yield2.52%
Payout Ratio30.94%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change27.39%
50-Day Moving Average2.68K
200-Day Moving Average2.32K
Relative Strength Index (RSI)54.31
Average Volume (3m)49.10K
Important Dates
ASKA Pharmaceutical Holdings Co., Ltd. upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
ASKA Pharmaceutical Holdings Co., Ltd. as a current ratio of 2.76, with Debt / Equity ratio of 4.67%
Current Ratio2.76
Quick Ratio1.45
Debt to Market Cap0.17
Net Debt to EBITDA-1.18
Interest Coverage Ratio26.28
Taxes
In the past 12 months, ASKA Pharmaceutical Holdings Co., Ltd. has paid 1.37B in taxes.
Income Tax1.37B
Effective Tax Rate0.20
Enterprise Valuation
ASKA Pharmaceutical Holdings Co., Ltd. EV to EBITDA ratio is 10.31, with an EV/FCF ratio of 16.02.
EV to Sales0.85
EV to EBITDA10.31
EV to Free Cash Flow16.02
EV to Operating Cash Flow9.54
Balance Sheet
ASKA Pharmaceutical Holdings Co., Ltd. has ¥7.23B in cash and marketable securities with ¥13.77B in debt, giving a net cash position of -¥6.54B billion.
Cash & Marketable Securities¥7.23B
Total Debt¥13.77B
Net Cash-¥6.54B
Net Cash Per Share-¥227.20
Tangible Book Value Per Share¥2.38K
Margins
Gross margin is 48.01%, with operating margin of 8.20%, and net profit margin of 7.63%.
Gross Margin48.01%
Operating Margin8.20%
Pretax Margin9.83%
Net Profit Margin7.63%
EBITDA Margin8.20%
EBIT Margin8.20%
Analyst Forecast
The average price target for ASKA Pharmaceutical Holdings Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.90%
EPS Growth Forecast6.20%